Latest Us Market News

Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.

EBR Systems has completed the first commercial US implants of its FDA-approved WiSE wireless cardiac resynchronization therapy system, marking a pivotal step toward broader market adoption and reimbursement.

BetMakers Technology Group launches a $13.5 million equity raise to fund the acquisition of Las Vegas Dissemination Company and strengthen its financial position amid improving operational metrics.

BetMakers Technology Group has raised A$12.5 million through an institutional placement and plans a further A$1 million via a Share Purchase Plan, positioning itself for strategic expansion and debt repayment.

Proteomics International has completed a $12 million capital raise, including a heavily oversubscribed Share Purchase Plan, to fast-track the rollout of its innovative diagnostic tests in Australia and the USA.

PainChek has advanced its US regulatory approval process with a positive FDA meeting, setting the stage for a potential market debut of its pain assessment app in late 2025.

QuickFee Limited has launched a A$1.5 million capital raising to fund expansion of its loan books in the US and Australia, following a quarter of record revenue and positive earnings before tax. The fintech also completed a major refinancing and revised its earnings guidance due to a credit impairment provision.

BetMakers Technology Group reports solid Q3 FY25 financial gains alongside a strategic binding agreement to acquire Nevada’s LVDC, expanding its global racing technology footprint.

Adveritas Limited reports a record 61% increase in annualised recurring revenue, driven by strong gains in sports betting and new product launches, while preparing for a strategic expansion into North America.

Pacific Edge has successfully raised NZ$16 million through an upsized equity placement, surpassing its initial target and setting the stage for a planned NZ$5 million Share Purchase Plan. The funds aim to accelerate clinical and commercial milestones, including regaining Medicare coverage for its cancer diagnostic tests.

IDP Education has revised its FY25 guidance, forecasting a sharp decline in student placements and language testing volumes due to persistent immigration policy uncertainty across key markets including the UK, Australia, Canada, and the US.